1. Home
  2. CBUS vs NORD Comparison

CBUS vs NORD Comparison

Compare CBUS & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cibus Inc.

CBUS

Cibus Inc.

N/A

Current Price

$1.23

Market Cap

116.2M

Sector

Industrials

ML Signal

N/A

NORD

Nordicus Partners Corporation Common Stock

N/A

Current Price

$2.78

Market Cap

95.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
CBUS
NORD
Founded
2010
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Professional Services
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
116.2M
95.5M
IPO Year
2017
2005

Fundamental Metrics

Financial Performance
Metric
CBUS
NORD
Price
$1.23
$2.78
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $12.00
N/A
AVG Volume (30 Days)
★ 108.8K
14.4K
Earning Date
11-12-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 74.33
31.25
EPS
N/A
★ N/A
Revenue
★ $3,639,000.00
$3,346.00
Revenue This Year
$39.09
N/A
Revenue Next Year
$107.71
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.02
$2.14
52 Week High
$4.19
$5.28

Technical Indicators

Market Signals
Indicator
CBUS
NORD
Relative Strength Index (RSI) 45.80 25.62
Support Level N/A $2.14
Resistance Level $1.65 $3.31
Average True Range (ATR) 0.17 0.47
MACD 0.02 -0.06
Stochastic Oscillator 42.58 28.51

Price Performance

Historical Comparison
CBUS
NORD

About CBUS Cibus Inc.

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

About NORD Nordicus Partners Corporation Common Stock

Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.

Share on Social Networks: